Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

被引:33
作者
Ascierto, Paolo Antonio [1 ]
Fox, Bernard A. [2 ]
Urba, Walter J. [2 ]
Anderson, Ana Carrizosa [3 ]
Atkins, Michael B. [4 ]
Borden, Ernest C. [5 ]
Brahmer, Julie R. [6 ]
Butterfield, Lisa H. [7 ]
Cesano, Alessandra [8 ]
Chen, Daniel S. [9 ]
de Gruijl, Tanja D. [10 ]
Dillman, Robert O. [11 ]
Drake, Charles G. [12 ]
Emens, Leisha A. [13 ]
Gajewski, Thomas F. [14 ]
Gulley, James L. [15 ]
Stephen Hodi Jr, F. [16 ]
Hwu, Patrick [17 ]
Kaufman, David [18 ]
Kaufman, Howard L. [19 ]
Lotze, Michael T. [20 ]
McNeel, Douglas G. [21 ]
Margolin, Kim A. [22 ]
Marincola, Francesco M. [23 ]
Mastrangelo, Michael J. [24 ]
Maus, Marcela, V [25 ]
Parkinson, David R. [26 ]
Romero, Pedro J. [27 ]
Sondel, Paul M. [28 ]
Spranger, Stefani [29 ]
Sznol, Mario [30 ]
Weiner, George J. [31 ]
Wigginton, Jon M. [32 ]
Weber, Jeffrey S. [33 ]
机构
[1] Fdn G Pascale, IRCCS, Ist Nazl Tumori, Naples, Italy
[2] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[5] Univ Wisconsin, Ctr Clin Canc, Madison, WI USA
[6] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[7] Parker Inst Canc Immunotherapy, Res, San Francisco, CA USA
[8] ESSA Pharma Inc, Redwood City, CA USA
[9] IGM Biosci Inc, Mountain View, CA USA
[10] Vrije Univ, Amsterdam Univ Med Ctr, Med Oncol, Canc Ctr Amsterdam, Amsterdam, Netherlands
[11] AIVITA Biomed Inc, Irvine, CA USA
[12] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA
[13] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[14] Univ Chicago, Immunol & Canc Program, Pathol & Med, Chicago, IL 60637 USA
[15] NCI, Bethesda, MD 20892 USA
[16] Dana Farber Canc Inst, Boston, MA 02115 USA
[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[18] Bill & Melinda Gates Med Res Inst, Cambridge, MA USA
[19] Immuneering Corp New York, New York, NY USA
[20] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[21] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[22] City Hope Natl Med Ctr, Med Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[23] Refuge Biotechnol, Menlo Pk, CA USA
[24] Thomas Jefferson Med Coll, Philadelphia, PA USA
[25] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
[26] ESSA Pharma Inc, Palo Alto, CA USA
[27] Univ Lausanne, Oncol, Lausanne, VD, Switzerland
[28] Univ Wisconsin, Pediat, Madison, WI USA
[29] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[30] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[31] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA
[32] MacroGenics Inc, Rockville, MD USA
[33] NYU Langone Med Ctr, Laura & Isaac Perlmutter Comprehens Canc Ctr, New York, NY 10016 USA
关键词
immunomodulation; inflammation mediators; CYTOKINE RELEASE SYNDROME;
D O I
10.1136/jitc-2020-000878
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页数:3
相关论文
共 11 条
[1]  
Ascierto PA, COMMUNICATION
[2]   Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies [J].
Maude, Shannon L. ;
Barrett, David ;
Teachey, David T. ;
Grupp, Stephan A. .
CANCER JOURNAL, 2014, 20 (02) :119-122
[3]   COVID-19: consider cytokine storm syndromes and immunosuppression [J].
Mehta, Puja ;
McAuley, Daniel F. ;
Brown, Michael ;
Sanchez, Emilie ;
Tattersall, Rachel S. ;
Manson, Jessica J. .
LANCET, 2020, 395 (10229) :1033-1034
[4]   Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group [J].
Puzanov, I. ;
Diab, A. ;
Abdallah, K. ;
Bingham, C. O., III ;
Brogdon, C. ;
Dadu, R. ;
Hamad, L. ;
Kim, S. ;
Lacouture, M. E. ;
LeBoeuf, N. R. ;
Lenihan, D. ;
Onofrei, C. ;
Shannon, V. ;
Sharma, R. ;
Silk, A. W. ;
Skondra, D. ;
Suarez-Almazor, M. E. ;
Wang, Y. ;
Wiley, K. ;
Kaufman, H. L. ;
Ernstoff, M. S. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[5]   Pilot Study of Tocilizumab in Patients with HIV and Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease [J].
Ramaswami, Ramya ;
Lurain, Kathryn ;
Widell, Anaida ;
Polizzotto, Mark N. ;
Goncalves, Priscila H. ;
Lindsley, Matthew ;
Steinberg, Seth M. ;
Whitby, Denise ;
Uldrick, Thomas S. ;
Yarchoan, Robert .
BLOOD, 2018, 132
[6]  
SANOFI, SAN REG BEG GLOB KEV
[7]   Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade [J].
Stroud, Chipman R. G. ;
Hegde, Aparna ;
Cherry, Cynthia ;
Naqash, Abdul R. ;
Sharma, Nitika ;
Addepalli, Srikala ;
Cherukuri, Sulochana ;
Parent, Teresa ;
Hardin, Jessica ;
Walker, Paul .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) :551-557
[8]   Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia [J].
Teachey, David T. ;
Lacey, Simon F. ;
Shaw, Pamela A. ;
Melenhorst, J. Joseph ;
Maude, Shannon L. ;
Frey, Noelle ;
Pequignot, Edward ;
Gonzalez, Vanessa E. ;
Chen, Fang ;
Finklestein, Jeffrey ;
Barrett, David M. ;
Weiss, Scott L. ;
Fitzgerald, Julie C. ;
Berg, Robert A. ;
Aplenc, Richard ;
Callahan, Colleen ;
Rheingold, Susan R. ;
Zheng, Zhaohui ;
Rose-John, Stefan ;
White, Jason C. ;
Nazimuddin, Farzana ;
Wertheim, Gerald ;
Levine, Bruce L. ;
June, Carl H. ;
Porter, David L. ;
Grupp, Stephan A. .
CANCER DISCOVERY, 2016, 6 (06) :664-679
[9]   Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China [J].
Wang, Zhongliang ;
Yang, Bohan ;
Li, Qianwen ;
Wen, Lu ;
Zhang, Ruiguang .
CLINICAL INFECTIOUS DISEASES, 2020, 71 (15) :769-777
[10]  
Xu Xiaoling, EFFECTIVE TREATMENT